Microglial priming in Alzheimer’s disease

Jun-Wei Li1, Yu Zong2, Xi-Peng Cao3, Lin Tan2, Lan Tan1,2

1Department of Neurology, Qingdao Municipal Hospital, Dalian Medical University, Qingdao 266000, China; 2Department of Neurology, 3Clinical Research Center, Qingdao Municipal Hospital, Qingdao University, Qingdao 266071, China

Contributions: (I) Conception and design: L Tan; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: JW Li, Y Zong, XP Cao; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Lan Tan. Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, No.5 Donghai Middle Road, Qingdao 266071, China. Email: dr.tanlan@163.com.

Abstract: Alzheimer’s disease (AD) is a chronic and progressive neurodegenerative disease of central nervous system (CNS). Nowadays, increasing evidence suggests that immune system plays a significant role in the mechanisms of AD’s onset and progression. Microglia, the main participant in the immune system of CNS, is always regarded as a protector of our brain in a healthy state and also has a beneficial role in maintaining the homeostasis of CNS microenvironment. However, chronic and sustained stimulation can push microglia into the state termed priming. Primed microglia can induce the production of amyloid β (Aβ), tau pathology, neuroinflammation and reduce the release of neurotrophic factors, resulting in loss of normal neurons in quantity and function that has immense relationship with AD. The therapeutic strategies mainly aimed at modulating the microenvironment and microglial activity in CNS to delay progression and alleviate pathogenesis of AD. Overall, in this review, we highlight the mechanism of microglial priming, and discuss the profound relationship between microglial priming and AD. Besides, we also pay attention to the therapeutic strategies targeting at microglial priming.

Keywords: Alzheimer’s disease (AD); amyloid beta (Aβ); microglial priming; neuroinflammation; tau-protein

Submitted Feb 26, 2018. Accepted for publication Apr 03, 2018.
doi: 10.21037/atm.2018.04.22

View this article at: http://dx.doi.org/10.21037/atm.2018.04.22

Introduction

Alzheimer’s disease (AD) has become the most common type of dementia among elders, especially those who are more than 65 (1). Now, it is known that the two main hallmarks of AD are the extracellular deposition of amyloid β (Aβ) in the form of neuritic plaques and the intracellular accumulation of abnormal tau proteins in neurofibrillary tangles (NFTs). Those pathological changes, directly or indirectly, induce loss of synaptic function, mitochondrial damage, microglial activation and neuronal cell death as consequences (2,3). However, the pathogenesis of AD is not clear and the treatment measures are not perfect. Currently, plenty of studies have been done and a wealth of evidence indicates that the activation and priming of microglial cells contribute to AD pathogenesis and progression.

Microglia, accounting a small part about 10–15% of all the glial cells, generally belong to resident innate immune system of central nervous system (CNS) and have an indispensable impact on brain (4). Microglial cells contribute to the detection of and the response to changes in the physiological and pathological condition by altering their morphology, phenotype and function (5). In a normal physiological state, microglial cells serve as sentinels to continuously monitor their surroundings. Once the homeostasis of the brain was disrupted, microglia will change into the formation of amoeba-like shape actively, expressing various antigens and becoming more phagocytic (6). If the imbalance of homeostasis in CNS is continuous, the microglial cells will be activated in a much stronger state, which is called “priming”. Microglial priming, as mentioned above, is
one step further in activation. Primed microglia are more sensitive to second stimulating factors and have a much stronger potential for reacting to the stimulating factors and even normal cells. The nature of primed microglia is a “double-edged sword” (5,7). In fact, they are derived from diverse phenotypes of microglia, and the phenotypes are context-dependent, which is related to the sequence and duration of their exposure to various stimuli in different pathologies (8,9). In this review, we highlight the effect of primed microglial cells on CNS, especially in the progression of AD.

The role of microglia in CNS

Microglia are the resident macrophages of the CNS, which are considered as the most versatile cells in brain (8). They are derived from mesoderm bone marrow precursor cells in the mesodermal yolk sac (10), and distributed throughout the brain of different densities from one site to another, much obvious in midbrain substantia nigra compacta, which has close relation to cognition. Microglia keep in a ‘quiescent’ or ‘resting’ state when their microenvironment is stable. They have a small cell body and morphological branches extending to all directions so as to survey and maintain the normal function of CNS actively (11) and slight changes in their microenvironment can translate microglia into ‘activated’ state. In a nutshell, a wealth of evidence indicates that microglia have an irreplaceable role in brain development and are important in synaptic pruning and clearing cell debris (12-14). Moreover, microglia form immune surveillance system of human brain and regulate critical processes associated with AD pathology, including the clearance and uptake of Aβ and abnormal tau protein as well as the production of neurotrophic factors and neuroinflammatory factors.

The priming of microglia

Microglial priming is a second interruption in brain microenvironment which induces an exaggerated or heightened microglial response compared to the first interruption referring to “microglial activation”, and primed microglia in CNS are more sensitive to potentially minor stimuli. This amplified response involves the change of microglial proliferation, morphology, physiology and biochemical markers (phenotype) (15,16). In consequence, these changes will lead to higher cytokines and inflammation mediator production which have immense impact on synaptic plasticity, neuronic survival, individual cognitive and behavioral function.

Mechanisms of microglial priming

A major element regulating microglia is the CNS microenvironment, for example, age (17-19). Increased oxidative stress, lipid peroxidation and DNA damage are associated with brain aging (17). Another factor for microglial priming is traumatic brain injury; significant evidence indicates that traumatic CNS injury causes prolonged activation of microglia and the development of the primed microglial profile. Massive studies show that both focal and diffuse traumatic brain injury induce formidable inflammatory process in the brain mediated by resident microglia and astrocytes (20,21). Then, the CNS infection is also a facet of the priming of microglia and viruses are the main causative agents of CNS infection. Both DNA and RNA viruses can trigger the priming of glial cells including microglia and astrocytes (22). Besides, some new studies show that complement dysfunction can change the expression of complement receptors of the immunoglobulin family on special tissue-resident macrophages and then trigger microglial priming following the activation by taking part in innumerable processes including synapse maturation, immune product clearance, hematopoietic stem/progenitor cells (HSPC) mobilization, lipid metabolism and tissue regeneration (23,24). In addition, there is also increased priming of microglia in pre-symptomatic neurodegenerative disease. For example, microglia with a morphologically activated phenotype are found in large numbers in brain (8). In the past several years, emerging lines of evidence have suggested that intricate neuroinflammation as a significant contributor to the priming of microglia, and all the above situations are closely related to neuroinflammation (17,21-23). In the context of the above situations, microglia are primed though a series of proinflammatory stimuli, such as lipopolysaccharide (LPS) (25), pathogenetic proteins (e.g., Aβ) (26,27), asynuclein (28), human immunodeficiency virus (HIV)-Tat (29,30), mutant huntingtin (31), mutant superoxide dismutase 1 (32) and chromogranin A (27).

There are various signaling pathways and it is well known that different kinds of cells express special pattern recognition receptors (PRRs) which can prime inflammatory signaling pathways. For example, some signaling pathways termed pathogen-associated molecular patterns (PAMPs) that customarily accumulate in infected tissue could monitor microbial molecules. In addition, aggregated
histocompatibility complex II (MHC II), interleukin-1 exacerbating inflammation with increased markers of main the release of neurotrophic factors, thus inducing the species (ROS), proinflammatory cytokines and reduces inducible nitric oxide syntheses (iNOS), reactive oxygen with TLR4 signaling, which promotes the excretion of activation) requires interferon-γ (IFN-γ) and M2 phenotypes (37,38). M1 polarization (classical environmental impetus, are able to differentiate M1 and M2 phenotypes (37,38). M1 polarization (classical activation) requires interferon-γ (IFN-γ) combined with TLR4 signaling, which promotes the excretion of inducible nitric oxide synthases (iNOS), reactive oxygen species (ROS), proinflammatory cytokines and reduces the release of neurotrophic factors, thus inducing the exacerbating inflammation with increased markers of main histocompatibility complex II (MHC II), interleukin-1β (IL-1β) and CD68 (39,40). M2 polarization (alternative activation) is considered to contribute to tissue-supportive in the situation of wound healing, tending to depress inflammation and promote tissue repairment of collagen form. They occur in response to IL-4 and IL-13 in vivo and predominate. M2 polarization is characterized by increased expression of neurotrophic factors, proteases, enzymes arginase 1 (ARG1), IL-10 transforming growth factor-β (TGF-β), scavenger receptor CD206 and coagulation factors, and it enhances phagocytic activity (41). In fact, there is no clear boundaries between the polarizations, and M1 phenotype shares many characteristics with M2 phenotype (42). Recently, another phenotype of primed microglia called acquired deactivation has been identified. This new phenotype overlaps with M2 and has the ability for anti-inflammatory and functional recovery (43). In addition, a team conducted ultra-structural analyses and discovered a bran-new phenotype named “dark microglia” which is seldom seen in stationary state instead of in aging or AD (44).

In healthy individuals, systemic inflammation translates microglia into a transient activated state in order to promote tissue and cell recovery and make a turn to homeostasis. However, microglial priming is the second interruption in CNS microenvironment, which is much more complex than the initial activation. The primed microglia is a double-edged sword (45) for brain stability and health. On one hand, considerable researches in vivo and in vitro have demonstrated that neuronal injury is associated with microglial activation (46,47). The inflammatory phenotypes (mainly about M1) of microglia release neurotoxic factors, mediators and ROS that are detrimental to CNS (46). On the other hand, primed microglia (mainly about M2) have an important and beneficial role in neuronal regeneration, repair and neurogenesis (41,48). Primed microglia respond much vigorously to brain injury, inflammation and aging challenge, and boost the activation by switching from an anti-inflammation, potentially protective phenotype (M2) to a pro-inflammation destructive phenotype (M1) (42) (Figure 1).

In the early stage of priming, the ability and activity to phagocytize cell debris, misfolded proteins, and inflammatory medium are increased, and more protecting molecules like IL-4, IL-13, IL-1RA, and scavenging receptors (45) are secreted. Thus, those changes can hasten normal progression of wound healing, even damage tissue repairment, neuron protection and homeostasis recovery (49). Over time, classical activated microglia (M1) account for a large proportion in all of the microglia and induce an intensive excretion of neurotoxic factors, such as IL-1β, TNF-α, NO and H2O2 (6), and more microglia are primed soon afterwards. This amplified and prolonged neuroinflammation induced by primed microglia can participate in the formation and clustering of protein tau and Aβ, furthermore it can lead to loss of neurons, decline of cognition and memory, for example, in AD patients (8,50). Although the mechanisms are not clear enough, people have reached an agreement that primed microglia...
incline to a chronic proinflammatory response and a self-perpetuating cycle of neurotoxicity. And this is a key factor to enhance the process of neuron damage, resulting in neurodegenerative diseases (6).

**Microglial priming in AD**

Aging of the CNS relate to a proinflammatory status including changes in the function of microglia. Extracellular Aβ deposition and phosphorylated tau protein accumulation in NFTs are the main neuropathological hallmarks in AD (51). Both of the neuropathological hallmarks are closely associated with activated microglia and astrocytes that are linked to neurodegenerative disease by the synthesis and secretion of inflammatory mediators, such as iNOS, ROS and proinflammatory cytokines. However, microglial priming is also mainly induced by the inflammation in CNS. Thus, whether microglial priming is the consequence or the cause of inflammation is still controversial (52). Microglial priming mainly induces a boost of Aβ, tau protein, neuroinflammation and reduction of neurotrophic factors, resulting in loss of normal neurons and formation of neuritic plaques and neurofibrillary tangles that have immense relationship with AD. With the progression of AD, changes from neuronal dysfunctions (still have no obvious signs and symptoms) to memory loss and cognitive impairment are becoming more visible.

**Microglial priming in Aβ**

Aβ is the main component of neuritic plaques, meanwhile Aβ is a series of 37–43 amino acid peptides, which are generated in the procedure of sequential enzymatic cleavage of amyloid precursor protein (APP) by β-secretase and γ-secretase (53). Microglia have a variety of receptors on the surface combined with Aβ, such as the RAGE and SR (54). Evidence confirms the notion that microglial priming caused by inflammation is an inducer of the accumulation of Aβ in AD rather than a primary cause of neurodegeneration (55,56). And from many studies, we summarize a conclusion that the activation of microglial cells is enhanced (microglial priming) under proinflammatory conditions, indicating that activated microglia responding to Aβ related proteins can critically rely on the priming of glial cells by proinflammatory factors (52). However, microglia and astrocytes have been found by studies to play important roles in engulfing and purging Aβ plaques as well as in remodeling cerebrovascular Aβ deposits in a cerebral amyloidosis mouse model that has been transformed in the gene (57). In the last few years, a point has been accepted by most people about the accumulation and clearance of Aβ plaques. For one thing, Aβ adheres to microglia and promotes their synthesizing and secreting of inflammatory mediators, which accelerates the progress of AD. For another, Aβ plaques are eliminated by activated microglia via phagocytosis and clearance (50).

Like other amyloid proteins, two subtypes of Aβ (Aβ1-40 and Aβ1-42) with different performances, higher aggregation degree Aβ (58) and soluble Aβ (sAβ) oligomers. And Aβ inclines to aggregate and change its conformation to become an unsolvable form named fibrillar Aβ (fAβ) (59). And it has been identified that oligomeric sAβ is more neurotoxic than fAβ. The oligomers alone are not toxic and stimulate a distinct secretory profile for IL-6 and monocyte chemoattractant protein-1 when compared...
with fibrils. Finally, soluble oligomers stimulate the loss of cultured cortical neurons which was accelerated via priming of microglia (60). There is also another statement that oligomers contribute to the early phase of AD, while Aβ in the fiber form has a main role in lasting the inflammatory response (61). One experiment with triple fluorescence labeling indicates that activated microglia participate in Aβ engulfing in microglial somata. Taking into account the intense relation between Aβ deposition and increased microglial cell density, we believed that Aβ aggregation might play a key role in the core mechanism for enhancing microglial density (2). Activated microglia were shown to migrate to newly formed amyloid plaques rapidly (62), indicating that they might transform their shape into an amoeba-like form aiming at Aβ plaque deposits and might contribute to pathology. In recent times, numerous imaging studies made the presence and progression of Aβ plaques out of water (63,64). Increased plaques may be hampered by priming and removing of microglia. Studies in transgenic mouse models indicated that primed microglia become dysfunctional in late-stage AD with decrease in the expression of Aβ-binding receptors and continuous reduction of enzymes, while maintaining even increasing the production of proinflammatory cytokines (65). Although it has long been believed that activated microglia are associated with Aβ plaques, and their explicit impact on the AD progression is still not entirely distinct at present (66).

Microglial priming in tau

Tau becomes a research hot spot in study of neurodegenerative disease after Aβ (50,67). Tau is a kind of microtubule-associated protein playing a significant role in neuronal microtubular stabilization and in axonal outgrowing promotion. Nevertheless, tau aggregation is recognized as tauopathies the common characteristic in many degenerative diseases (68).

Tau oligomers and fibrils are prompted via arachidonic acid, and then they prime the microglia with significant changes in morphology (69). Many experiments suggest the release of extracellular tau by neurons and cell lines via diverse pathways, including cell death (70). Emerging lines of study show that human extracellular tau collection is internalized by microglia. The extracellular tau can be internalized by other cells, including glial cells and neurons. The pattern from cell to cell of tau spreading has been proposed as one of the mechanisms underlying the progression of tau pathology (71,72). Wild type of human tau protein is transforming from ventral hippocampus to next neurons that connects to each other discounting the distance, and the example indicating a trans-synaptic protein transfer is olfactory and limbic systems (71,73).

Activated microglia also plays an opposing role in tau pathogenesis after priming in AD. On one side, they result in the beginning of the disease via liberation neurotoxins, such as proinflammatory mediators and ROS (46,74,75). Meanwhile, activated microglia standing by NFTs participating in the tangle formation show the envelopment of activated microglia in tau pathology. On the other side, triggered microglia restrain the progression of AD by phagocytosing abnormal cumulated, highly phosphorylating tau protein. In addition, activated microglia can synthesize and release numerous neurotrophic factors and antioxidant to resist the pathology of AD (48,75).

Microglial activation contributes to neurodegeneration because immunosuppression depresses the intracellular tangles and neuronal loss in mice expressing mutant tau (76). In the last few years, increasing devotion in modeling and genetics in AD mice has indicated that a defective or abnormal response of microglia has an indispensable role in the synergistic interaction motivating between intracellular NFTs and extracellular Aβ plaques. Thus, this balance is disrupted, leading to the pathology of tau spreading and accelerating the progression to AD (1). Cognitive decline and memory impairment keep in pace with the pathology progression of tau spreading to all cortical regions. In all these advanced stages, it has been discovered that tau pathology is always accompanied with ‘neuritic’ amyloid plaques combined with NFTs that are composed of aggregated hyperphosphorylated tau (77). Microgliosis might be the earliest manifestation of neurodegenerative tauopathies, and abrogation of tau-induced microglial activation could retard the progression of CNS disorders (76,78). Though considerable endeavor and progress have been made in recent years about the role of tau in degenerative diseases, the detail and accurate mechanisms of tau pathology associated with microglia and tau mediated disease are still under water.

Microglial priming in neuroinflammation

Though the precise and detailed role of microglial cells remains to be ascertained and elucidated, there is a consensus on that primed microglia are involved in AD-associated inflammation response of the CNS (66,79). It has been verified that neuroinflammation induced by microglial...
priming mainly about aging, systemic inflammation, gene regulation and blood brain barrier impairment.

Aging
Aging is the main risk factor for the onset and progression of AD, especially for the sporadic forms (80) and is accompanied by chronic, systemic up-regulation of the proinflammatory factors and a relative decrease in anti-inflammatory answer (81,82). This shift from homeostasis to an inflammatory state is via age-linked elements which induce an imbalance between anti-inflammatory and proinflammatory networks (83). Microglia is primed into an activated state that can amplify the persistent neuroinflammation and inflammatory reactivity in the aged brain (81). A vast of studies have indicated that microglia in the brain of rodent model act in a triggered phenotype during aging characterized with increased expression of CD11b, CD11c and CD68 (84).

Systemic inflammation dependent
Recently, considerable evidence has emerged that the neuroinflammation cascades deduced from primed microglia cells also lead to the AD pathogenesis (85,86). Prolonged activation of microglia can enhance the synthesis and secretion of proinflammatory cytokines and trigger a proinflammatory cascade, consequently resulting in neuronal damage and losses (8,87). Neuroinflammation is not only an early event but a hand pushing the progression of AD. And microglia have an indispensable impact on the inflammation of human brain (88). The CNS inflammation and sickness behaviors can be deduced from systemic inflammation through molecular pathways. A study of Spencer et al. indicates that ROS production of primed microglia reduces the levels of intracellular glutathione and increases nitric oxide production in NADPH oxidase subunit NOX2. Moreover, they identify that these simultaneously occurring processes lead to the production of more neurotoxic peroxynitrite (89). And this has been verified many times in rodent models that are challenged before with peripheral LPS or administration of one or more of the proinflammatory cytokines such as TNF-α, IL-1β and IL-6, IL-33 (38,81,90). The results of immense researches come to an agreement on the opinion that systemic inflammation can lead to microglial activation (91). The consequence of this research highlights the variability of inflammatory response in brain associated with AD patients and the underlying relationship between systemic inflammatory and neuroinflammation (Table 1). Besides, MAPK (mitogen activated protein kinase) signaling pathways are highly evolutionarily and widespread conserved the function of regulate mechanisms of the eukaryotic cell, and microglial MAPK can also lead to an inflammatory response to the aged brain with AD (92). Overall, chronic or prolonged systemic inflammation induces neuroinflammation, leading to the onset and accelerating the progression of AD (93,94).

Genetic regulation dependent
In the ageing human brain, gene regulation associated with the innate immune response has been observed.
Recently, preclinical, bioinformatics and genetic data have revealed that activation of the brain immune system relates to AD pathology and leads to the pathogenesis of this disease (95). Genome wide association studies (GWAS), functional genomics (96,97) and even proteomic analysis of cerebrospinal fluid (CSF) and blood (98,99) have identified that dysfunctional immune pathways deduced from genic mutation as indispensable susceptibility factors in LOAD (100), which is the vast majority of AD. Recently, GWAS have become a powerful tool in screening genes and several new risk genes associated with AD have been identified. Apolipoprotein E (APOE) ε4 allele is the most significant and common risk gene for sporadic AD, and this mutation exacerbates the risk of disease onset by 15 times in homozygous carriers and by three times in heterozygous carriers (101,102). Two further studies have plunk for the presumption of compromised microglial function through distinguishing rare mutations that have an increased risk of AD (97,103). An extracellular domain mutation of TREM2 gene has a similar extent with APOE ε4 in increasing the risk of AD. While TREM2 is highly expressed on the surface of microglia (104) and mediates phagocytosis and the removing of neuronal debris (105). In addition, some other genes, such as PICALM, Bin1, CLU, CRI, MS4A4 and CD33 have been identified as risk genes for AD (106,107). Most of the risk mutation genes are expressed by microglial cells (108).

Blood-brain barrier (BBB) impairment dependent

BBB is between blood and brain, and it is a special barrier mainly formed by tight liner sheets, specific endothelial cells and tight junctions—structures that bring those cells together (51,109). The CNS is important for our body, and BBB is indispensable for CNS. The BBB combined with blood-nerve barrier form a frontier defense system to restrict the communications of cells and soluble factors between blood and the neural tissue, and it has a significant role in maintaining the homeostasis of CNS and peripheral nervous system (110). With development, sustained inflammation can cause damage to the BBB. During the insult and depending on the time, this damage could lead to loss of hypersensitive neurons, and neuroinflammatory sites and focal white matter impairment emerge after the damage (86,100,111). Besides, compromised BBB allows more infiltrating leukocytes to enter into CNS (112); an immune response was aggravated by brain microglia under the condition of peripheral inflammation. These processes are under the control of chemokine and cytokine signaling and have an effect on brain microglial cells (112). For instance, it has been verified that TNF-α, IL-17A and IL-1β can loosen the tight junctions and destroy the BBB. Loss of BBB integrity and altered expression of tight junctions are associated with neuroinflammatory response (51,113). Several studies have indicated that in the animal model of AD the vulnerability of BBB to inflammation is increased and current knowledge indicates that the BBB integrity is more important than previous and modulation of the BBB may provide a new therapeutic target for the treatment of AD (114) (Figure 2).

Microglial priming in surrounding cells

The relationship between microglial activation and neighbor cells, especially neurons, is omnifarious and still not completely clear. However, studies have identified that the sustained release by primed microglia of proinflammatory mediators has an effect on the suppression of neurogenesis in adults and axonal transport (115,116). In addition, neuroinflammation deduced from activated microglia restricts the supplement of neurotrophic factors to surrounding cells (116,117) and may affect interneuronal protein handling process which is important for brain physiology. Activated microglial cells affect surrounding neurons and even cause detrimental feedback on microglia in degenerative disease, especially in AD (116). Neurodegeneration starts on distal axonal segments usually, and affects neuron progression proximally to culminate in the death in a dying-back process. Combined with microglial priming, synaptic pathology is the earliest neurotoxic consequence in progressive neurodegeneration (76). Microglial priming deduced from chronic or prolonged microglial activation increases the level of proinflammatory cytokines by accelerating the synthesis and release, and also triggers a proinflammatory cascade leading to neuronal damage and losses later (8,87). There is amplified axon impairment which is associated with cytokines and iNOS released by primed microglial cells (118). Thus, activated microglia probably play a detrimental role in surrounding tissue mainly through the expression of proinflammatory mediators.

Therapeutic interventions

In a study, the risk factors of AD in old people are randomly allocated to a combined life-style of diet, exercise, individual
recognized training, standard care and strict control over the risk factors of cardiovascular diseases (119). And in pairs, a meta-analysis has identified that effective interventions in diet, exercise, medications, psychological condition, biochemical exposures, preexisting disease and lifestyle may reduce new incidence rate of AD (120,121). It has been identified that microglial activation has a close relationship with the progression of tau pathology and considerable studies in animal models of AD have approved that modulating the activation of microglial cells, by and large, is a powerful and effective method to prevent the main pathological events including aggradation of Aβ plaque, tau pathology and neuronal loss. And some researches also demonstrate that it is destructive rather than protective of microglia in the condition of undirected or uncontrolled activation (76,122). Modulating microglial priming can be implemented by improving the microenvironment in CNS, altering activated microglial phenotype.

Nowadays, several kinds of drugs are mainly utilized to treat the patients with AD: rivastigmine, galantamine, cholinesterase inhibitors donepezil and glutamate antagonist memantine (119). And a wide range of clinical trials have identified that anti-inflammation drugs such as NASIDs (123), statins (124) and TNF blockers (81) can reduce the incidence of AD in a long time. Those drugs can reduce the detrimental effect of proinflammatory cytokines on neuronal function and of proinflammatory cytokines on the aggradations of Aβ plaques (81). Recently, GWAS studies have confirmed that microglial receptors such as CD36 and RAGE are greatly up- or down-regulated after being activated in the brain of AD patients with genic mutation (108). Besides, neuroinflammation is greatly aggravated in Rag-5xf AD mice (an immune-deficient mouse model with AD that lacks B cells, T cells, and natural killer cells) as indicated by a shift in microglial phenotype, reducing phagocytic capacity and increasing proinflammatory mediators production, and immune cell populations are also important in the progression of AD pathology (125). Current researchers are devoting their energy into identifying the pathways in special that can be
targeted efficiently and practically. For instance, it has been demonstrated that blocking the signaling pathway of IL-1β can ameliorate the pathology of CNS in mouse models with AD (122,126). In addition, a new study has verified that administration of TNF-α monoclonal antibody (infliximab) of AD or regulating glucose metabolism can reduce amyloid plaques and phospho-tau (127). Restricting the priming and overactivation of microglia can be a powerful targeting method to treat AD. Treatment strategies designed in the future to counteract the adverse effects of overactivation in these cells should be researched more than ever (128).

**Conclusions and future perspectives**

Microglia play a beneficial role in maintaining the homeostasis of CNS micro-environment; if the balance of the brain homeostasis is disturbed, microglial cells can be activated and do their best to restore the balance in CNS by defending against the destructors and protecting the aboriginal roles. However, chronic and sustained stimulation can push microglia into a state named priming, which is more sensitive to potentially minor stimuli. Microglial priming mainly induces the boost of Aβ, tau protein, neuroinflammation and reduction of neurotrophic factors, resulting in loss of normal neurons and formation of neuritic plaques and neurofibrillary tangles that have immense relationship with AD. This “double-edged sword” inclines to a detrimental role and can accelerate the progression of abnormal protein production and aggravation as well as neuronal loss and dysfunction. Although we have a clear view that aging has great relevance to AD, we can do nothing about it. Thus, the therapeutic strategies mainly aimed at modulating the microenvironment in CNS by reducing inflammation to delay progression and alleviate pathogenesis of AD and modulating microglial reactivity could be equal to a meaningful approach. Besides, primed microglia also can improve the abilities in engulfing abnormal substances and releasing neurotrophic factors. However, the detailed mechanisms of microglial priming and its functions are not completely clear. But as more and more scientists and researchers focus on it, the method to ameliorate even cure AD is not far away from us.

**Acknowledgements**

This work was supported by grants from the Shandong Provincial Outstanding Medical Academic Professional Program, Qingdao Key Health Discipline Development Fund, Qingdao Outstanding Health Professional Development Fund, and Shandong Provincial Collaborative Innovation Center for Neurodegenerative Disorders.

**Footnote**

*Conflicts of Interest:* The authors have no conflicts of interest to declare.

**References**

13. Norden DM, Muccigrosso MM, Godbout JP. Microglial...


